Oxford Biomedica (LON:OXB) Earns Buy Rating from Peel Hunt

Key Points

• Oxford Biomedica's stock received a **"buy" rating** from Peel Hunt, with a target price of GBX 451 ($5.99), indicating a potential downside of **1.64%** from its current price.
• JPMorgan Chase has downgraded its price objective for the company's shares from GBX 490 ($6.51) to GBX **400 ($5.31)**, setting a **"neutral" rating**.
• Insider Heather Preston purchased **11,389 shares** at an average price of GBX 324 ($4.30), demonstrating insider confidence as corporate insiders now hold **21.17%** of the company's stock.

Oxford Biomedica (LON:OXB - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Peel Hunt in a research report issued on Friday, Marketbeat.com reports. They presently have a GBX 451 ($5.99) target price on the biopharmaceutical company's stock. Peel Hunt's target price would suggest a potential downside of 1.64% from the stock's current price.

Separately, JPMorgan Chase & Co. dropped their price objective on shares of Oxford Biomedica from GBX 490 ($6.51) to GBX 400 ($5.31) and set a "neutral" rating for the company in a report on Tuesday, July 15th.

Oxford Biomedica Stock Down 1.3%

Shares of LON OXB opened at GBX 458.50 ($6.09) on Friday. The company has a 50 day simple moving average of GBX 347.95 and a 200 day simple moving average of GBX 333.58. The firm has a market cap of £487.39 million, a PE ratio of -3.41 and a beta of 1.09. Oxford Biomedica has a 1 year low of GBX 232.50 ($3.09) and a 1 year high of GBX 467.12 ($6.20). The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67.

Insiders Place Their Bets

In related news, insider Heather Preston acquired 11,389 shares of Oxford Biomedica stock in a transaction dated Tuesday, June 17th. The stock was bought at an average price of GBX 324 ($4.30) per share, with a total value of £36,900.36 ($48,997.96). Corporate insiders own 21.17% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.